Guidepoint Qsight has been tracking the U.S. Peripheral Thrombectomy market, capturing a growth rate of +56.6% from 3Q19 to 3Q20.
Following the launch of the Indigo Lightning 12 catheter, Penumbra’s market share grew 6 points (31.5% in 3Q19 vs. 37.5% in 3Q20).
In just one year, Inari Medical, the newest player in the market, grew its share to 29.7%, rapidly capturing nearly a third of the market as of September 2020.
Boston Scientific and BTG were historically the two major players dominating the peripheral thrombectomy market, with Boston Scientific acquiring BTG in 2019. However, Inari and Penumbra combined have managed to eclipse Boston Scientific.
The above is based on Qsight’s healthcare facilities purchasing dataset analyzing over $62M from the three dominant players in the U.S. Peripheral Thrombectomy market across a panel of over 500 distinct healthcare facilities and hospitals.
Post created by: Kenny Dolgin, VP of Quantitative Research, Guidepoint Qsight & Shimul Sheth, Quantitative Analyst, Guidepoint Qsight